Conference

More Information

Marketing Pharma Europe 2010 

30. Nov – 1. Dec 2010, Carlton Tower Hotel, London, UK

Draft Agenda – Marketing Pharma Europe

08:00  Registration Coffee

09:00  Chairman’s opening remarks

09:10  Presentation: The Future of Pharma: Research Insights and Implications for Marketers

  • What evolutionary concepts tell us about the future of pharma
  • The new competitive habitat in global pharma
  • The capabilities needed to survive rapid evolutionary change
  •  The role of marketing in the future of pharma

Dr Brian D Smith, CEO, Pragmedic

09:50  Q&A with keynote speakers

INTEGRATING MARKETING, COMMUNICATION, SALES AND R&D FOR A GLOBAL STRATEGY

10:00  Presentation: Creating a global strategy for a winning marketing portfolio

  • Integrated key-opinion leader management
  • Stakeholder management to align global marketing efforts

Rebecca Joslin, Associate Brand Director - Exelon Patch, Novartis

10:30  Networking coffee and refreshments

11:10  Presentation: Delivering results through ROI analysis

  • Why ROI is important
  • Why ROI fails to deliver
  • The 4 steps in a good ROI analysis
  • Case study: A comparison of different approaches
  • Making ROI work in your organization

Graham Leask, Management Strategy Group, Aston University

11:40  Designing the Pharmaceutical Selling Organization for the 21st Century

  • Learn why more sophisticated pharma sales models require new approaches to sales force design
  • Maximize customer impact by matching capabilities with customer needs 
  • Ensure an optimal sizing by balancing bandwidth and workload
  • Create KAM roles that are designed for successZS Associates, speakers to be announced

Chris Murray, Manager, ZS Associates London

12:10  Speed networking

13.00  Networking lunch

14:40  Presentation: R&D as a future marketing tool

  • The current role of R&D in a marketing cycle
  • Is a closer linkage between R&D and marketing necessary?
  • R&D as the missing link in early stage marketing

15:10   Presentation: Early-Stage Pharmaceutical Marketing challenges within the Public-Private Partnership model

  • Introduction stage of enlightenment
  • Moving from the private to the public market
  • Scaling up difficulties
  • Closing the deal
  • Getting the balance right

Pierre Hugo, Associate Director - Product Development, Medicines for Malaria Ventures (MMV) 

15:40 Networking coffee and refreshments
 
16:10  Presentation: Improving Corporate Social Responsibility via Public-Private Partnerships

  • Socially responsible deals
  • Ensuring the dissemination and commercialization of safe, efficacious andaffordable treatments for developing countries
  • The product-development public-private partnership funded by philanthropy as a model for global health impact
  • The MMV partnering and funding strategies to defeat the neglected disease Malaria: 10 years of success and challenges
  • A global health impact leveraging both private and public goods

Prof. Patrick Nef, PhD, CBO, Medicines for Malaria Ventures (MMV)


16:40  Chairman's closing remarks

17:00   Networking Reception


Day 2

08:30  Registration coffee and refreshments

09:00  Chairman’s opening remarks

INCORPORATING DIGITAL MARKETING AND SOCIAL MEDIA

09:10  Presentation: 5 reasons why Pharma should not do E-marketing

  • E-detailing vs. visit
  • Banner ads vs. print ads
  • Newsletter vs.mailing
  • Search engine marketing
  • Social media

Martin Hensen, Head of eStrategies, UCB

09:40   
Presentation: Understanding the changes of customer and physicians behaviour  

  • How physician behaviour has changed and how it influences the market landscape
  • What are the challenges and opportunities?
  • What measures need to be taken to evaluate, analyse and react?
  • Strategies and new approaches Effectively approch the taskso f monitoring and reporting

Carwyn Jones, Head of Pharmaceutical Sales & Marketing, Doctors.net.uk

10:10  Case study: Getting social

  • Why pharma needs to lead the way and lag behind with the personal web
  • Developing engagement in a regulated environment
  • Understanding Social strategy and aligning across the business
  • Looking beyond platforms
  • Insight into some Janssen social media projects 

Alex Butler, Digital Strategy and Social media Manager, Jansen-Cilag

10:40  Networking coffee and refreshments


11:10 Presentation: Architecture of an eChannel. Digital elements to build a Multichannel promotional model

  • Why an e-Channel
  • Digital assets: tablet PCs, web 3.0, e-detailing
  • Combining digital assets to create a promotional platform
  • Trasforming data into a CRM knowledge center

Juan Ramon Amoros, e-Business Manager, Boehringer Ingelheim

11:40 
Presentation: Understanding the opportunities of e-detailing

  • E-detailing as the missing gap between digital marketing and sales
  • Experiences with e-detailing applications
  • Analysis of e-detailing ROI

Wanda Laskowska-Studniarska, MD, PhD, Digital Business Manager, Sanofi Aventis

12:10  Case study: Achieving a CRM project success

  • CRM project - Facts and challenges
  • Mastering the key points: prioritise requirements, stakeholders expectations, vendor selection, usage policy, user motivation, customer data validation
  • Hemofarm CRM - project overview

Darko Ružić, CRM Manager, Trade Marketing Service, Marketing, Hemofarm AD

12:40  Presentation: Pharma and social media: an uneasy marriage?

  • Why does social media represent such a legal challenge for pharma?
  • What guidance is there to help?
  • Sensible strategies for managing the legal and compliance risks

Tim Worden, Partner, Taylor Wessing

13:10  Networking lunch

BEST PRACTICE LIFE CYCLE MARKETING AND R&D

14:40  Stakeholder Wars: A New Hope

  • How to interact with your stakeholders optimally and what does that mean?
  • A view of the new stakeholder ecosystem in which we operate and how we can better understand it and interact with it
  • Analysis of pharma companies performing well in key stakeholder groups and tackle the recent trend of measuring stakeholder satisfaction to compensate an organisation.

Mark Sales, Head of Global Brand & Stakeholder Management, Brand & Stakeholder Management, Kantar Health

15:10  Presentation: Uniting R&D and Marketing for Integrated Early-  Stage Market Preparation

  • Benefits of combining R&D and marketing efforts for more efficient marketing and increased ROI
  • Bridging the gap between R&D and marketing in early-stage drug development
  • Portfolio planning, resource allocation, product hand-offs and ownership

Mike Rea, Principal, Idea Pharma

15:40  Networking coffee and refreshments 

16:10  Presentation: Early stage marketing  

  • Creating awareness of the clinical need
  • Marketing the clinical value message
  • Defining the Influencers
  • Internal linkage of medical and marketing

Brian Lovatt, CEO, Vision Healthcare Consultancy

16:40  Chairman’s closing remarks

16:50 Close of conference

LinkedIn
http://www.redkiteconsulting.com
EPG Health Media
Boomerang